fldm - FLDM STOCK NEWS

Fluidigm Corporation (Nasdaq:FLDM) announced stockholder approval for a strategic capital infusion from Casdin Capital and Viking Global Investors, amounting to $225 million in convertible preferred shares. This investment aims to enhance growth opportunities in mass cytometry and microfluidics technologies. The agreement also includes the conversion of existing loans into shares. Following the transaction, Fluidigm will rebrand as Standard BioTools Inc. and trade under the new symbol 'LAB'. The report of final voting results will be filed with the SEC.

Fluidigm (Nasdaq: FLDM) announced a support agreement with Caligan Partners, its largest stockholder, for a strategic capital infusion transaction with Casdin Capital and Viking Global Investors. Caligan will vote 'FOR' all related proposals at the reconvened Special Meeting on April 1, 2022. If the transaction closes, Dr. Frank Witney, endorsed by Caligan, will join Fluidigm's Board, increasing its members to eight. The Board emphasizes the importance of stockholder votes, warning that failure to approve the proposals may terminate the purchase agreements.

Fluidigm Corporation (NASDAQ:FLDM) announced a critical meeting for stockholders to vote on proposals related to a necessary capital infusion from investors Casdin Capital and Viking Global Investors. The special meeting will reconvene on April 1, 2022, and failure to secure stockholder approval will lead to termination of the proposed agreements. The Board of Directors emphasized the urgency due to financial uncertainties, risking relationships with customers and employees. Fluidigm's stock has shown a 32% increase since the announcement compared to peers' 19% decrease, underscoring market support.

Fluidigm Corporation (NASDAQ:FLDM) has adjourned its Special Meeting of Stockholders to April 1, 2022, to give stockholders more time to consider a $250 million strategic capital infusion from investors Casdin Capital and Viking Global Investors. This infusion includes a prior $25 million in loans and aims to accelerate growth and optimize costs. The company plans to rebrand as Standard BioTools Inc. post-investment, enhancing its focus in the life sciences sector. Stockholders eligible to vote were recorded as of February 18, 2022.

Fluidigm Corporation announced a strategic capital infusion of $250 million from investors Casdin Capital and Viking Global Investors. This funding aims to enhance growth initiatives and optimize cost structure. A special stockholder meeting on March 25, 2022, will address related proposals. The investment, which includes $25 million received in January, is anticipated to accelerate innovation in the life sciences sector and maximize value for stakeholders. Key areas of focus include growth in mass cytometry and targeted opportunities in microfluidics.

Fluidigm Corporation (Nasdaq: FLDM) announced its Q4 and full-year 2021 financial results, revealing total Q4 revenue of $38.3 million, down from $44.6 million YoY. Base product revenue increased by 13.5% to $35.3 million. The company reported a GAAP net loss of $9.4 million, improved from a loss of $18.0 million in Q4 2020. COVID-19 testing revenue plummeted by 70.2% to $2.8 million. The company anticipates a $250 million capital investment from Casdin Capital and Viking Global to support growth initiatives. A name change to Standard BioTools Inc. is also planned.

Fluidigm Corporation (Nasdaq: FLDM) announced a collaboration with Abu Dhabi Stem Cells Center (ADSCC) to develop targeted stem cell therapies using Fluidigm's mass cytometry technologies, including Imaging Mass Cytometry and Maxpar Direct Immune Profiling Assay. This partnership aims to enhance the visibility of mass cytometry in the Middle East and facilitate new customer acquisition. ADSCC will gain early access to Fluidigm’s emerging products and participate in product development discussions, potentially leading to commercialization opportunities.

Fluidigm Corporation (Nasdaq:FLDM) has filed a preliminary proxy statement for a special stockholder meeting to vote on a strategic capital infusion from Casdin Capital and Viking Global Investors. The proposed investment totals $250 million, aimed at driving organic and inorganic growth initiatives and optimizing costs. Following the investment, Fluidigm plans to rebrand as Standard BioTools Inc. Stockholder approval and satisfaction of closing conditions are needed for the investment, which includes $25 million previously raised in term loans.

Fluidigm Corporation (NASDAQ: FLDM) has announced a $250 million investment from Casdin Capital and Viking Global Investors to fuel growth initiatives and optimize its cost structure. The investment follows a review aimed at maximizing shareholder value and will help the company transition to Standard BioTools Inc., emphasizing its commitment to life sciences. New leadership includes Dr. Michael Egholm as CEO and Alex Kim as COO. The investment will focus on expanding mass cytometry and microfluidics platforms, enhancing the company's offerings for the biopharma sector.